CST: 03/12/2016 05:32:39   

Israeli Patent Office Issues Notice of Allowance to NanoVibronix Allowing All Claims of Patent Application for System and Method for Surface Acoustic Wave Treatment of Skin

255 Days ago

ELMSFORD, NY --(Marketwired - March 22, 2016) - NanoVibronix, Inc, (OTCQB: NAOV), a medical device company, has announced that the Israeli Patent Office has issued a notice of allowance for our system and method for surface acoustic wave treatment of skin. The patent will be granted following payment for patent issuance, which will be done this month. This patent has already been granted in China, and is in the final phase of being granted in the U.S. as well. The patent covers our Surface Acoustic Wave (SAW) technology as it relates to wound healing, reduction of pain, drug delivery, and cosmetic rejuvenation of skin.

William Stern, PhD Chief Executive Officer of NanoVibronix, stated, "We are pleased with the progress we have made in securing additional world-wide patents using our Surface Acoustic Wave technology. With the Israeli Notice of Allowance, soon to be followed by a U.S. patent, we will be able to add cosmetic skin rejuvenation to our list of medical and cosmetic applications for our technology. We are developing a device for the facial rejuvenation market called Renooskin. Previous in vitro clinical studies on human skin were done showing that the SAW technology provided skin rejuvenation comparable to Retinol A, a well accepted anti-aging cream. The Company is developing a head band like applicator for the SAW treatment and has arranged for a pilot trial with a cosmetic dermatologist. The Company believes that pending proving efficacy of the Renooskin and receiving regulatory approval, the device can be sold in a non-reimbursement market since cosmetic devices are exclusively private pay. We expect first article testing to be completed by Q3 of 2016."

About NanoVibronix 

NanoVibronix Inc. is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company's groundbreaking technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications. The devices accelerate wound healing and provide pain relief. The devices can also be administered at home, without the assistance of medical professionals. The company's products include PainShield® and WoundShield™, which both have CE Mark . The PainShield™ also has FDA clearance. NanoVibronix's catheter based products include the UroShield™ and NG-Shield™ that are both CE Marked . Additional information about the company is available at: www.nanovibronix.com.

SAFE HARBOR STATEMENT: This release contains certain statements that are, or may be deemed to be, forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934, and are made in reliance upon the protections provided by such Acts for forward-looking statements. We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form SEC filings.

Contact:

Rodd Leeds or Natalya Rudman
Crescendo Communications, LLC
Email: naov@crescendo-ir.com
Tel: 212-671-1020